LongCovid
Statement by Dr Hans Henri P. Kluge, WHO Regional Director for Europe to the press on COVID-19, extreme heat and mpox. Statement – 36 million people across the…
New relevant publication on The Lancet! “An inhaled Covid vaccine booster was more than 5-fold effective for inducing neutralizing antibodies at 28-days, and more durable at 1-year, than…
Interesting literature review published by The Lancet with an analysis of studies that looked for the persistence of SARS-CoV-2 RNA or antigens in children. This article suggests that, independent from…
The new article by Professor Louise Cummings (Department of English and Communication, The Hong Kong Polytechnic University) examines in detail the language and cognitive difficulties associated with many Long COVID patients.…
Currently, there are no curative therapies for Post-COVID or ME/CFS. A German study led by Charité – Universitätsmedizin Berlin proposes the evaluation of drugs targeting different mechanisms in clinical trial networks using harmonized diagnostic…
On the occasion of its first year of implementation, the Long COVID project just launched a new Press Release. Do not miss it! All Long COVID Press Releases…
Very interesting article published by Nature Communication on the natural history of the Long COVID in Scotland Study (Long-CISS), a Scotland-wide, general population cohort of adults. The study…
Very interesting interview with University of California San Francisco infectious disease specialist Michael Peluso, who co-leads one of the world’s oldest studies of the debilitating condition. What’s New…
Annals of Clinical and Translational Neurology recently published this article where the authors identified that the kynurenine pathway relates to post-acute COVID-19 objective cognitive impairment and PASC. This opens…
A new perspective article published by Frontiers in Medicine proposes a multipronged clinical trial platform approach that addresses the complexity and heterogeneity of Post-COVID and ME/CFS, enabling to test numerous drugs in…